(Q46654172)

English

Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization

scientific article published in March 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18400585

Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18400585

author name string

Yao-Yuan Hsieh

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18400585

Chi-Chen Chang

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18400585

Horng-Der Tsai

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18400585

publication date

1 March 2008

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18400585

Taiwanese Journal of Obstetrics & Gynecology

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18400585

47

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18400585

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18400585

66-74

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18400585

Effects of gonadotrophin-releasing hormone agonists (GnRHa) on follicle and oocyte quality

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Subcutaneous goserelin versus intranasal buserelin for pituitary down-regulation in patients undergoing IVF: a randomized comparative study.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The long-acting gonadotropin-releasing hormone analogues impaired the implantation rate

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of a single half-dose, long-acting form of gonadotropin-releasing hormone analog (GnRH-a) and a short-acting form of GnRH-a for pituitary suppression in a controlled ovarian hyperstimulation program.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of short 7-day and prolonged treatment with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462)

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal stimulation using recombinant follicle-stimulating hormone and a gonadotropin-releasing hormone antagonist in women of advanced age.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized study of D-Trp6-LHRH versus buserelin in long desensitization protocols for medically assisted conception cycles.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison between depot and standard release triptoreline in in vitro fertilization: pituitary sensitivity, luteal function, pregnancy outcome, and perinatal results

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Endocrinology: Prospective randomized study of clomiphene citrate and gonadotrophins versus goserelin and gonadotrophins for follicular stimulation in assisted reproduction

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of long- and short-acting forms of gonadotrophin-releasing hormone analogues in women undergoing oocyte donation

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison between a standard and reduced dose of D-Trp-6-luteinizing hormone-releasing hormone administered after pituitary suppression for in-vitro fertilization.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Subcutaneous low dose leuprolide acetate depot versus leuprolide acetate for women undergoing ovarian stimulation for in-vitro fertilization.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gonadotropin-releasing hormone and reproductive medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (Ganirelix) administered by intranasal spray

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gonadotrophin-releasing hormone antagonists: will they replace the agonists?

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of gonadotrophin releasing hormone (GnRH) antagonist (cetrotide) during ovarian stimulation for in-vitro fertilization treatment: multiple doses and single dose

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of gonadotropin-releasing hormone antagonist in a flexible protocol: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective randomized study comparing gonadotropin-releasing hormone agonists or gonadotropin-releasing hormone antagonists in couples with unexplained infertility and/or mild oligozoospermia.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

GnRH antagonist improved blastocyst quality and pregnancy outcome after multiple failures of IVF/ICSI-ET with a GnRH agonist protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles--a prospective, randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gonadotropin-releasing hormone antagonist: new tools vs. old habits

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

LH stimulation of estrogen secretion by cultured rat granulosa cells

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

No influence of body weight on pregnancy rate in patients treated with cetrorelix according to the single- and multiple-dose protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

GnRH antagonist in assisted reproduction: a Cochrane review

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow?

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The benefits of mid-luteal addition of human chorionic gonadotrophin in in-vitro fertilization using a down-regulation protocol and luteal support with progesterone

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960057-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1028-4559(08)60057-1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18400585

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18400585

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46654172&oldid=2124350982"